This is the text extract for August Tender Notification, browse documents here.

---

31 August 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009. Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly. Product Notification Forms Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm 10th September 2010. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp. July Tender Notification - corrections Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 1. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on 1 September 2010, reference pricing of nontender winning brand will occur on 1 November 2010 and Sole Subsidised Supply commences on 1 February 2011.

Chemical Name Ceftriaxone sodium Presentation; Pack size and type Inj 500 mg; 1 injection, vial Current subsidy and price $3.99 New subsidy and price $2.70* Sole supply brand (Supplier) Veracol (Multichem)

*The new subsidy and price indicated in the July notification was incorrect.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 2. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 September 2010; DV Limits will apply from 1 November 2010; delisting of the other brand in Section H will occur on 1 November 2010.

The decisions were as follows:

Chemical Name Ceftriaxone sodium Ceftriaxone sodium

Presentation; Pack size and type Inj 500 mg; 1 injection, vial Inf 2 g; 1 injection, vial

Current pack price $3.99 $10.50

New pack price $2.70* $5.20*

Hospital Supply Brand (Supplier) Veracol (Multichem) Veracol (Multichem)

DV Limit 1% 1%

A358383 - qA15909

---

Chemical Name

Presentation; Pack size and type

Current pack price

New pack price

Hospital Supply Brand (Supplier)

DV Limit

*The new brand prices indicated in the July notification were incorrect.

3. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 December 2010; DV Limits will apply from 1 February 2011; delisting of the other brand in Section H will occur on 1 February 2011.

The decisions were as follows:

Chemical Name Ondansetron Ondansetron

Presentation; Pack size and type Tab 4 mg; 30 tablets, blister Tab 8 mg; 10 tablets, blister

Current pack price $17.18 (per 10 tablets) $33.89 (per 20 tablets)

New pack price $5.10* $1.70*

Hospital Supply Brand (Supplier) Dr Reddy’s (Dr Reddy’s) Dr Reddy’s (Dr Reddy’s)

DV Limit 1% 1%

*The new brand prices indicated in the July notification were incorrect

March Tender Notification - correction 4. Fluoxetine hydrochloride 20 mg capsules, 84 pack (Fluox (Mylan)) will be Sole Supply Status from 1 December 2010, not 1 October 2010 as notified in the March 2010 Tender Notification. Fluoxetine hydrochloride 20 mg capsules, 90 pack (Fluox (Mylan)) will be delisted from Section B of the Pharmaceutical Schedule on 1 December 2010. 2008/09 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 5. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on 1 October 2010, reference pricing of nontender winning brand will occur on 1 December 2010 and Sole Subsidised Supply commences on 1 March 2011.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type Eye drops 0.5%; 10 ml OP, bottle

Current subsidy and price $2.40

New subsidy and price $1.28

Chloramphenicol

Sole supply brand (Supplier) ArrowChloramphenicol (Arrow)

Brands affected by reference pricing and delisting Chlorsig (Sigma)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 6. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 October 2010; DV Limits will apply from 1 December 2010; delisting of the other brand in Section H will occur on 1 December 2010.

The decisions were as follows:

Chemical Name Chloramphenicol

Presentation; Pack size and type Eye drops 0.5%;

Current pack price $2.40

New pack price $1.28

Hospital Supply Brand (Supplier) Arrow-

DV Limit 1%

Brand (supplier) to be delisted Chlorsig

A358383 - qA15909

Page 2 of 5

---

Chemical Name

Presentation; Pack size and type 10 ml, bottle Inj 2 mg per ml, 50 ml; 1 vial

Current pack price

New pack price

Hospital Supply Brand (Supplier) Chloramphenicol (Arrow)

DV Limit

Brand (supplier) to be delisted (Sigma) m-fluconazole (Multichem)

Fluconazole

$7.10

$5.68

Fluconazole-AFT (AFT)

1%

2009/10 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 7. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on 1 December 2010 and Sole Subsidised Supply commences on 1 March 2011.

Chemical Name Gemfibrozil Presentation; Pack size and type Tab 600 mg; 60 tablets, bottle Subsidy and price $14.00 Sole supply brand (Supplier) Lipazil (Douglas)

8. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 October 2010 and Sole Supply Status commences 1 January 2011.

The decisions were as follows:

Chemical Name Aciclovir Aciclovir Aciclovir Lorazepam Lorazepam Mercaptopurine

Presentation; Pack size and type Tab dispersible 200 mg; 25 tablets, blister Tab dispersible 400 mg; 56 tablets, blister Tab dispersible 800 mg; 35 tablets, blister Tab 1 mg; 250 tablets, bottle Tab 2.5 mg; 100 tablets, bottle Tab 50 mg; 25 tablets, bottle

New Current subsidy and subsidy and price price $1.98 $6.64 $7.38 $16.42 $11.17 $47.06 $1.98 $6.64 $7.38 $16.42 $11.17 $47.06

Sole supply brand (Supplier) Lovir (Douglas) Lovir (Douglas) Lovir (Douglas) Ativan (Sigma) Ativan (Sigma) Purinethol (Aspen)*

* Purinethol has been divested from GSK to Aspen Pharmacare

9. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on 1 October 2010, reference pricing of nontender winning brand will occur on 1 December 2010 and Sole Subsidised Supply commences on 1 March 2011.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type Tab 0.5 mg; 30 tablets, blister Tab 2.5 mg; 30 tablets, blister Tab 5 mg; 30 tablets, blister

Current subsidy and price $2.20 $4.10 (28 tablets) $6.01 (28 tablets)

New subsidy and price $0.95

Sole supply brand (Supplier) Zapril (Mylan)

Brands affected by reference pricing and delisting Inhibace (Roche)

Cilazapril

Cilazapril

$2.06

Zapril (Mylan)

Inhibace (Roche)

Cilazapril

$3.28

Zapril (Mylan)

Inhibace (Roche)

A358383 - qA15909

Page 3 of 5

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 10. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on 1 December 2010 and DV Limits will apply from 1 February 2011.

The decisions were as follows:

Chemical Name Gemfibrozil

Presentation; Pack size and type Tab 600 mg; 60 tablets, bottle

Pack Price $14.00

Hospital Supply Brand (Supplier) Lipazil (Douglas)

DV Limit 1%

11. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on 1 October 2010; DV Limits will apply from 1 December 2010.

The decisions were as follows:

Chemical Name Aciclovir

Presentation; Pack size and type Tab dispersible 200 mg; 25 tablets, blister Tab dispersible 400 mg; 56 tablets, blister Tab dispersible 800 mg; 35 tablets, blister Tab 1 mg; 250 tablets, bottle Tab 2.5 mg; 100 tablets, bottle Tab 50 mg; 25 tablets, bottle

Current pack price $1.98

New pack price $1.98

Hospital Supply Brand (Supplier) Lovir (Douglas)

DV Limit 1%

Aciclovir

$6.64

$6.64

Lovir (Douglas)

1%

Aciclovir

$7.38

$7.38

Lovir (Douglas)

1%

Lorazepam

$16.42

$16.42

Ativan (Sigma)

1%

Lorazepam

$11.17

$11.17

Ativan (Sigma)

1%

Mercaptopurine

$47.06

$47.06

Purinethol (Aspen)*

1%

*Purinethol has been divested internationally from GSK to Aspen Pharmacare

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 4 December 2009.

The decisions were as follows:

Chemical Name Caffeine citrate Caffeine citrate Desferrioxamine mesylate Domperidone Ethinyloestradiol with levonorgestrel Gentamicin sulphate

Line Item Inj 10 mg per ml, 2.5 ml Oral liq 10 mg per ml Inj 500 mg Tab 10 mg Tab ethinyloestradiol 30 mcg with levonorgestrel 50 mcg (6) and ethinyloestradiol 40 mcg with levonorgestrel 75 mcg (5), and ethinyloestradiol 30 mcg with levonorgestrel 125 mcg (10) and 7 inert tab Powder BP

A358383 - qA15909

Page 4 of 5

---

Chemical Name Glimepiride Glimepiride Glimepiride Glimepiride Menthol Methotrexate Methotrexate Methotrexate Methotrexate Methotrexate Methotrexate Methylcellulose Methyl hydroxybenzoate Morphine sulphate Morphine sulphate Pravastatin Pravastatin Pravastatin Pravastatin Propylene glycol Sodium bicarbonate Sulphur

Line Item Tab 1 mg Tab 2 mg Tab 3 mg Tab 4 mg Crystals Inj 10 mg per ml, 0.5 ml prefilled syringe Inj 10 mg per ml, 0.75 ml prefilled syringe Inj 10 mg per ml, 1 ml prefilled syringe Inj 10 mg per ml, 1.5 ml prefilled syringe Inj 10 mg per ml, 2 ml prefilled syringe Inj 10 mg per ml, 2.5 ml prefilled syringe Powder Powder Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Liquid Powder BP Precipitated

For the remaining products on the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A358383 - qA15909

Page 5 of 5